Mohammed YA, Farouk HK, Gbreel MI, Ali AM, Salah AA, Nourelden AZ, Gawad MMA, et al.
Journal of foot and ankle research. Date of publication 2022 Sep 14;volume 15(1):71.
1. J Foot Ankle Res. 2022 Sep 14;15(1):71. doi: 10.1186/s13047-022-00575-y.
Human amniotic membrane products for patients with diabetic foot ulcers. do they
help? a systematic review and meta-analysis.
Mohammed YA(1)(2), Farouk HK(3)(4), Gbreel MI(3)(5), Ali AM(3)(6), Salah
AA(3)(6), Nourelden AZ(3)(7), Gawad MMA(3)(4).
Author information:
(1)Faculty of Medicine, Assiut University, Assiut, 71631, Assiut governorate,
Egypt. yasminea126@gmail.com.
(2)International Medical Research Association (IMedRA), Cairo, Egypt.
yasminea126@gmail.com.
(3)International Medical Research Association (IMedRA), Cairo, Egypt.
(4)Faculty of Medicine, Al-Fayoum University, Fayoum, Egypt.
(5)Faculty of Medicine, October 6 University, Giza, Egypt.
(6)Faculty of Medicine, Minia University, Minia, Egypt.
(7)Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
BACKGROUND: Diabetic foot ulcer (DFU) is one of the most serious diabetic
complications. DFU is an open wound that usually occurs in the foot sole due to
poor blood glucose control, peripheral neuropathy, and poor circulation. The
human amniotic allograft membrane is a biological wound dressing derived from
the amniotic membrane. It contains amino acids, nutrients, cytokines, and growth
factors that make the growth process easier.
OBJECTIVE: To compare dehydrated human amnion and chorion allograft (DHACA) plus
the standard of wound care (SOC) with the SOC alone.
METHODS: We searched for randomized clinical trials (RCTs) on PubMed, Scopus,
Cochrane, and Web of Science till April 2021 using relevant keywords. All search
results were screened for eligibility. We extracted the data from the included
trials and pooled them as mean difference (MD) or risk ratio (RR) with the 95%
confidence interval (CI) using Review Manager software (ver. 5.4).
RESULTS: The pooled effect estimate from 11 RCTs showed that DHACA was superior
to SOC regarding the complete wound healing in both 6th and 12th week
(RR = 3.78; 95% CI: [2.51, 5.70]; P < 0.00001) and (RR = 2.00; 95% CI: [1.67,
2.39], P < 0.00001 respectively). Also, the analysis favored the DHACA regarding
the mean time to heal in the 12th-week (MD = -12.07, 95%CI: [-19.23, -4.91],
P = 0.001). The wound size reduction was better with DHACA (MD = 1.18, 95%CI:
[-0,10, 2.26], P = 0.03).
CONCLUSION: Using DHACA with SOC is safer and more effective than using SOC
alone for DFU patients.
© 2022. The Author(s).
DOI: 10.1186/s13047-022-00575-y
PMCID: PMC9472416
PMID: 36104736 [Indexed for MEDLINE]
Conflict of interest statement: None to declare.
